Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
Trial details
- Registry ID
- NCT04796324
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.NCT04796324 | Allarity Therapeutics | Phase 2 | Terminated | 2024-12-01Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |